- Home
- CADL
as 02-21-2025 4:00pm EST
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | NEEDHAM |
| Market Cap: | 306.4M | IPO Year: | 2021 |
| Target Price: | $19.75 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.74 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.34 - $14.60 | Next Earning Date: | 03-27-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Candel Therapeutics Inc. (CADL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Tyagarajan Seshu | CADL | Chief Technology Officer | Jan 15 '25 | Sell | $7.23 | 14,322 | $103,476.45 | 96,790 | |
| Tak Paul Peter | CADL | Chief Executive Officer | Jan 15 '25 | Sell | $7.23 | 21,704 | $156,811.40 | 251,912 | |
| Barone Francesca | CADL | Chief Scientific Officer | Jan 15 '25 | Sell | $7.23 | 13,534 | $97,783.15 | 110,673 | |
| Nichols William Garrett | CADL | Chief Medical Officer | Jan 15 '25 | Sell | $7.23 | 10,428 | $75,342.30 | 79,320 | |
| Schoch Charles | CADL | See Remarks | Jan 15 '25 | Sell | $7.23 | 9,511 | $68,716.97 | 43,038 | |
| Tyagarajan Seshu | CADL | Chief Technology Officer | Jan 8 '25 | Sell | $8.22 | 14,545 | $119,533.72 | 96,790 | |
| Tak Paul Peter | CADL | Chief Executive Officer | Jan 8 '25 | Sell | $8.22 | 21,172 | $173,995.73 | 251,912 | |
| Barone Francesca | CADL | Chief Scientific Officer | Jan 8 '25 | Sell | $8.22 | 13,673 | $112,367.45 | 110,673 | |
| Nichols William Garrett | CADL | Chief Medical Officer | Jan 8 '25 | Sell | $8.22 | 10,799 | $88,749.42 | 79,320 | |
| Schoch Charles | CADL | See Remarks | Jan 8 '25 | Sell | $8.22 | 9,971 | $81,943.67 | 43,038 |
Latest Candel Therapeutics Inc. News
CADL Breaking Stock News: Dive into CADL Ticker-Specific Updates for Smart Investing
MT Newswires
2 days ago
Citigroup Initiates Candel Therapeutics at Buy With $25 Price Target
Simply Wall St.
a month ago
Insider Stock Buying Of Candel Therapeutics Delivers Return On US$3.00m Investment
GlobeNewswire
a month ago
Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025
Pharma Voice
a month ago
After layoffs, a viral immunotherapy biotech bounced back with a late-stage prostate cancer win
MT Newswires
2 months ago
Candel Therapeutics Closes Securities Offering to Raise $92 Million
GlobeNewswire
2 months ago
Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
MT Newswires
2 months ago
Update: Candel Therapeutics Prices $80 Million Public Offering -- Shares Fall
MT Newswires
2 months ago
Top Midday Decliners
Compare CADL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CADL Candel Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.